Table 2 Clinicopathological characteristics according to HER2 protein expression intensity.
From: HER2 as a potential biomarker of lymph node metastasis in undifferentiated early gastric cancer
|  | Total (n = 680) | Negative (n = 462) | Borderline (n = 182) | Positive (n = 36) | p-value |
|---|---|---|---|---|---|
Age | Â | Â | Â | Â | <0.001 |
<60 | 340 (50.0%) | 252 (54.5%) | 76 (41.8%) | 12 (33.3%) | Â |
≥60 | 340 (50.0%) | 210 (45.5%) | 106 (58.2%) | 24 (66.7%) |  |
Sex | Â | Â | Â | Â | 0.002 |
M | 456 (67.1%) | 291 (63.0%) | 138 (75.8%) | 27 (75.0%) | Â |
F | 224 (32.9%) | 171 (37.0%) | 44 (24.2%) | 9 (25.0%) | Â |
Tumour size | Â | Â | Â | Â | 0.027 |
≤20 | 176 (25.9%) | 132 (28.6%) | 37 (20.3%) | 7 (19.4%) |  |
>20 | 504 (74.1%) | 330 (71.4%) | 145 (79.7%) | 29 (80.6%) | Â |
Vertical location | Â | Â | Â | Â | 0.928 |
UT/MT | 381 (56.0%) | 259 (56.1%) | 101 (55.5%) | 21 (58.3%) | Â |
LT | 299 (44.0%) | 203 (43.9%) | 81 (44.5%) | 15 (41.7%) | Â |
Gross appearance | Â | Â | Â | Â | 0.065 |
E | 109 (16.0%) | 68 (14.7%) | 31 (17.0%) | 10 (27.8%) | Â |
FD | 571 (84.0%) | 394 (85.3%) | 151 (83.0%) | 26 (72.2%) | Â |
Depth of invasion | Â | Â | Â | Â | <0.001 |
M | 343 (50.4%) | 259 (56.1%) | 70 (38.5%) | 14 (38.9%) | Â |
SM | 337 (49.6%) | 203 (43.9%) | 112 (61.5%) | 22 (61.1%) | Â |
Histology | Â | Â | Â | Â | <0.001 |
Differentiated | 316 (46.5%) | 177 (38.3%) | 110 (60.4%) | 29 (80.6%) | Â |
Undifferentiated | 364 (53.5%) | 285 (61.7%) | 72 (39.6%) | 7 (19.4%) | Â |
LVI | Â | Â | Â | Â | 0.017 |
No | 540 (79.4%) | 377 (81.6%) | 139 (76.4%) | 24 (66.7%) | Â |
Yes | 140 (20.6%) | 85 (18.4%) | 43 (23.6%) | 12 (33.3%) | Â |
Node metastasis | Â | Â | Â | Â | 0.296 |
No | 600 (88.2%) | 410 (88.7%) | 161 (88.5%) | 29 (80.6%) | Â |
Yes | 80 (11.8%) | 52 (11.3%) | 21 (11.5%) | 7 (19.4%) | Â |
